Member Info for Energyshares

🤡🤡🤡

There is a 🤡 out 🟩 them so can’t see which of the three 🤡’s is trolling but even on good news days the board is easier and quicker to read.

GLA

🤡🦭 just 🟩 him with the other two 🤡🤡’s

Revealing 10 new drugs on one day is a bit of information overload.

Avacta need to reveal one of the new drugs every other day in a RNS running up to science day.

That would give the market and investors time to take in the impact of the new drugs :ie: Market size

Competition

Animal results

If Pre/Cision generation 2 or 3

Possible partners.

Spreading out the reveal would give maximum impact for SP to recover.

GLA

Affimers for DX = plant based

Affimers for TX = Animal based

Complete different affimers different IP

I have a hunch that a Alistair Smith consortium is one of the bidders for the DX business.

Reasons:

He lost control of his life long company for his love affair for DX affimers.

He knows the business inside out.

He has a track record of raising substantial funds.

He has kept quiet on his exit unless he is under a NDA, and he walked away without a fight, but could have asked for the opportunity to bid for DX as part of his leaving negotiations.

His partner Gardiner has been his inside man on negotiations of the DX sale over the last few months.

Both him and Gardiner have had to sell millions of shares over the last few months and with their pay off from leaving the company are in a good position to offer PG’s to potential lenders.

Not long now for DX sale.

Just a hunch……

Chief £7.3 million first round

Last funding round was the 4th all undisclosed but there is 8 major funders most in from the start.

Korea are quite aggressive getting their pharma’s through trials

This is one to watch..

“Is this dead in the water? Haven’t heard anything about it for yonks”

30th September results:

Last paragraph of results report second to last sentence.

In September 2024. Affyxell therapeutics Co ltd, successfully completed a funding round,which Avacta did not participate in, thereby reducing the Group’s shareholding from 25% to 21%.

Avacta saving cash for AVA6000 trial but another successful funding completed

21% stake worth more than the £25% they had before this funding round.

Onwards this 3rd funding round for Affyxell complete.Avacta’s stake in Affyxell must be getting close to their market cap at the moment….

Then we have LG Chem and Lilly licence.

GLA…

Page 2 of TP Note today

Upcoming milestones

First two completed

3rd Box

Release of updated pipeline of Avacta TX assets with stage and timing to clinic.

In progress

Updates on the pipeline will be ongoing through October

4th box

Science day 30th October.

Any day they could announce a deal for one of these 10 assets or maybe a partnership for AVA6000

Traders will be playing Russian roulette this month.

LTH ‘s grab your popcorn and sit back….

Just had a peep, plenty of green twat boxes

🤡🟩🤡🟩🤡🟩

GLA the invested

Great find DR-dms

Look at this page AVA04 mentioned a lot

murine bladder cancer

colorectal cancer mentioned

Also drugs

Bevacizumab & Ipilimumab

Mentioned in patent.

https://worldwide.espacenet.com/publicationDetails/description?CC=IL&NR=311536A&KC=A&FT=D&ND=4&date=20240501&DB=EPODOC&locale=en_EP

🍕🤡🟩🍕🤡🟩🍕🤡🟩🍕🤡🟩🍕🤡🟩🍕🤡🟩🍕🤡🟩🍕🤡🟩🍕🤡🟩🍕🤡🟩🍕🤡🟩🍕🤡🟩🍕🤡🟩🍕🤡

See the 🟩🤡🤡🤡’s are camped here all day.

1/4 of all posts today

E🤡🤡Y

T🤡UK

WYNB🤡RE

Just green box the CL🤡WNS.

🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡

🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡

🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩🤡🟩

Any excuse for the CL🤡WNS to turn up

E🤡🤡Y

T🤡UK

WYNB🤡RE

Just filter makes the board easier to read..

Could win it this year

Finalist last year

WINNER

AffyImmune Therapeutics’ AIC100 ICAM-1 targeting CAR T cell therapy

FINALISTS

AffyImmune Therapeutics’ AIC100 ICAM-1 targeting CAR T cell therapy

Arvinas and Pfizer’s oral PROteolysis TArgeting Chimera (PROTAC) ER degrader vepdegestrant for breast cancer

Avacta Therapeutics’ AVA6000 pre|CISION tumour-targeted chemotherapy

Immuneering’s deep cyclic inhibition candidate IMM-1-104 for advanced RAS-mutant solid tumors

Kura Oncology’s menin inhibitor ziftomenib for multiple genetic subsets of acute myeloid leukemia

MSD/Moderna’s mRNA-4157/V940 investigational individualized neoantigen therapy

42 posts today

1 page board members who are invested

1 page off green box Fud 22 posts today

So easy to read board now…..

Love green boxes

E🤡🤡Y

T🤡UK

WYNB🤡RE

I have binned these 3 clowns the board so easy to read now, just scroll past blocks of green.

I didn’t realise how much Fud these three put out.